LESI | Print Page | Sign In | Join
Share |

LES 2015 Spring Meeting

Meeting Home | Schedule | Speakers | Continuing Education | Presentations


Joseph P. Allen
Andrea Belz
Bruce H. Bernstein
Bruce V. Bigelow
Kerrie Brady
Michael Bredahl
Cynthia Cannady
Tracie L. Carroll
Jeffrey Cozzo
Michael Crichton
Kirk Dailey
Joseph J. Daniele
Pamela Demain
Kristine Dorrain
Mark Edwards
Michael Elmer
J. Scott Evans
Standish Fleming
Brian Frizzell
Michael Grey
James H. Grossman
Lawrence (Larry) Hadley
Margaret Hing
Soonhee Jang
David W. Jones
Justin Lewis
Jack Lu
Douglas MacDougall
James A. McCarthy
Matthew McNeill
Mark Messenbaugh
Michael Milani
Ada Nielsen
Stacey Nunes
Niall O'Donnell
Brian P. O'Shaughnessy
Sandra Partridge
Afshin Pishevar
David Poon
Linda Pullan
Eric Reifschneider
Rajesh C. Shrotriya
Prathiba M. Singh
Jonathan D. Spangler
D. C. Toedt III
Scott Weingust
Jeffrey Whittle
David Winwood
Koenraad Wuyts

Joseph P. Allen, Director of the Office of Technology Commercialization, U.S. Department of Commerce
Joseph P. AllenJoe Allen served on the U.S. Senate Judiciary Committee for Senator Birch Bayh (D-IN) securing passage of the Bayh-Dole Act which fostered R&D partnerships between universities and U.S. industry. The Economist Technology Quarterly called this law “possibly the most inspired piece of legislation to be enacted in America over the past half century.” On leaving the Senate staff, Joe was Executive Director of Intellectual Property Owners, Inc. (IPO) before going to the U.S. Department of Commerce where he became the Director of the Office of Technology Commercialization. He was instrumental in the passage of major laws allowing U.S. industry to perform joint R&D with federal laboratories. Allen's office oversaw Executive branch implementation of technology transfer laws and related presidential policy directives. He helped negotiate intellectual property rights provisions for several international agreements. Joe became President of the National Technology Transfer Center established by Congress to promote industry/federal laboratory R&D partnerships. In 2008 he founded Allen and Associates a consulting firm specializing in technology management/IP issues. Joe was the lead witness before the South Africa parliament on their Bayh-Dole law. In 2013 he co-chaired the White House Lab to Market Summit. The Association of University Technology Managers presented Joe with the Driving Innovation Award “For His Tireless Work and Support as a Champion for the Bayh-Dole Act during the Past 30 Years.” He also writes a monthly column for IP Watchdog on technology management issues.

[back to top]

Andrea Belz, Managing Director, Kinetic Intelligence
Andrea Belz, the Director of the National Science Foundation Innovation Node - Los Angeles, serves as Entrepreneur-in-Residence (Technology) with faculty appointments in the Marshall School of Business, the Viterbi School of Engineering, and the Rosky School of Design. The Past Chair of the Los Angeles Chapter of LES, Dr. Belz is Managing Director of Kinetic Intelligence, an intellectual property strategy consultancy and has previously guided strategic planning for world-class innovators including Avery Dennison, BP, California Institute of Technology, CVI Melles Griot, Korea Institute for the Advancement of Technology, NASA's Jet Propulsion Laboratory, Occidental Petroleum, and UCLA; the author of The McGraw-Hill 36 Hour Course: Product Development, Dr. Belz has also consulted to many venture capital firms and university technology startups. She currently serves on the boards of ITUS and Caltech spinoff laser manufacturer Ondax. She holds a BS in physics from the University of Maryland at College Park, a PhD in physics from the California Institute of Technology, and an MBA in finance from the Pepperdine University Graziadio School of Business.

[back to top]

Bruce H. Bernstein, Co-Managing Partner, Greenblum & Bernstein
Bruce H. BernsteinMr. Bernstein is co-managing partner of Greenblum & Bernstein, a full service IP firm, and is a leader in the client counseling, licensing and technology transfer practice group. Mr. Bernstein is frequently involved in patent licensing negotiations on behalf of both licensors and licensees. Mr. Bernstein speaks Japanese and frequently travels to Japan and other areas in Asia, and often lectures on topics relating to patent monetization from both a legal and business perspective. Mr. Bernstein has also published on licensing issues, including as a co-author of the 2011 – 2015 editions of "Licensing U.S. Jurisdiction." Getting The Deal Through - in print and on-line, Law Business Research Ltd. He graduated from Tufts University with a B.S. degree in Applied Physics, and from Georgetown University Law Center with a JD Degree. He was an Examiner and law clerk at the USPTO Board of Appeals prior to entering private practice.

[back to top]

Bruce V. Bigelow, Editor, Xconomy San Diego
Bruce V. BigelowBruce is an experienced journalist with broad responsibilities and flexibility in writing about innovation in San Diego.

He is the San Diego editor for Xconomy, a Boston-based online media company focused on innovation, entrepreneurship, and the startup ventures that make up the 'exponential' economy (hence Xconomy). Xconomy now operates a network of websites in 10 U.S. cities renowned for their respective technology clusters. As the editor of Xconomy San Diego, he also is responsible for recruiting speakers for events like the Xconomy Napa Summit, where we put our most important stories on stage, and for convening Xconomy events that bring local innovation leaders together to discuss issues of vital interest to the local startup ecosystem.

He joined Xconomy from the San Diego Union-Tribune, where he spent 18 years covering business, technology, science and other subjects in the San Diego region.

He shared the 2006 Pulitzer Prize for National Reporting, awarded to The San Diego Union-Tribune for uncovering and detailing the Rep. Duke Cunningham bribery scandal; and national journalism awards for stories about defense contractor Titan Corp., whose employees sustained the highest casualty rate in Iraq (2006); a profile of securities class-action lawyer Bill Lerach (2000), and "The Toymaker," (1997), a 14-part narrative about the startup years of the Rokenbok Toy Co.

Bruce also followed the corporate financial fraud at San Diego's Peregrine Systems from 2002-2008.

[back to top]

Kerrie Brady, BPharm, MBA MS, Chief Business Officer, Centrexion
Kerrie BradyKerrie is the Chief Business Officer at Centrexion a US-based pharmaceutical development company seeking to develop a new class of therapeutics that stops pain at its source. Centrexion's non-opioid clinical stage product candidates selectively deactivate pain fibers to provide patients with long lasting relief. Its pipeline targets major unmet needs in the treatment of severe pain caused by human and canine osteoarthritis, nerve injury, and herpes zosterviral infection.

Kerrie is an experienced international biotechnology business executive with a successful 30-year track record in working with both entrepreneurial ventures and established companies. Drawing on her expertise in operations, business development, marketing, and regulatory affairs, she has forged strategic alliances to bring new products to market. She was formerly Chief Operations Officer of Vallinex, a position she held since 2010. Vallinex was formed as a spin out of the activities of Arcion Therapeutics. At Arcion Therapeutics Kerrie was a co-founder and served as Chief Operations Officer from 2007. While at Arcion, she was responsible for strategic management of operations to support the development of the clinical portfolio leading to the successful licensing of its lead product (ARC-4558 for treatment of painful diabetic neuropathy) to BioDelivery Sciences Inc in March 2013.

Prior to establishing Arcion, Kerrie founded Traxion Therapeutics Inc., where she had in-licensed global rights to three novel pain molecules from Japanese pharmaceutical companies, Mochida and Ajinomoto. Prior to Traxion, Kerrie was Vice President of Business Development at KMG Japan Inc. where she established partnerships between Japanese and Western companies. Kerrie has held senior business development positions with the U.S. biopharmaceutical companies, EntreMed and Intracell. Prior to moving to the United States, Ms. Brady spent 15 years in the Asia-Pacific region working with pharmaceutical companies, biotech companies, and research organizations in the commercial development and marketing of new and emerging technologies. Ms. Brady began her career in the healthcare industry with regulatory and marketing positions at Rhone Poulenc.

She has a Bachelor of Pharmacy from the Victorian College of Pharmacy, an MBA (Award of Distinction) from the University of Melbourne, and a Masters in Science (Biopharmaceuticals) from the University of New South Wales.

[back to top]

Michael Bredahl, Leader of the International IP Ownership/Royalty Model, Cargill, Inc.
Michael Bredahl has over 25 years of intellectual asset management, business development and IP valuation experience. He currently leads the global IP ownership and royalty model and is a Senior Advisor in the corporate business development team at Cargill Incorporated. Prior to Cargill Michael was Principal of a consultancy he founded as well as a Senior Manager at Deloitte and PricewaterhouseCoopers. While at PwC Michael was a founder of their Intellectual Asset Management consulting practice. Over the course of his career, he has also served as an adviser to numerous angel and venture capital groups concerning the business plans, strategy and early-stage technology value of technology-based start-ups.

[back to top]

Cynthia Cannady, Principal and Founder, IPSEVA
Cynthia CannadyCynthia Cannady is a principal and founder of IPSEVA , an international network of professionals who provide IP services to private and public clients to promote development and commercialization of sustainable energy technology. She is an expert in intellectual property strategy and technology licensing. She holds a juris doctor degree from Harvard Law School and a bachelor degree with honors from Stanford University. She is a member of the Bars of the State of California and the District of Columbia.
Prior to founding IPSEVA in 2007, Mrs. Cannady was Director of the Intellectual Property and New Technologies Division at the World Intellectual Property Organization (WIPO) in Geneva, Switzerland, where her responsibilities included direction of activities and international training programs relating to IP strategy, licensing, technology transfer, valuation, and IP asset management. (2001-2007). Her professional experience has included: Principal, Tech Law Group, Menlo Park, California (1997 to 2001); Apple Computer, Vice President of Law for Manufacturing and Development, Cupertino, California (1993 to 1997); Partner, Litigation, Fenwick & West, Palo Alto, California (1984 to 1992); Attorney, Williams and Connolly (1980-1983); Attorney Advisor in the Office of the Legal Advisor, United States Department of State (1977-1980); law clerk to Judge Alvin B. Rubin in the United States District Court for the Eastern District of Louisiana (1975-1977).

She is currently a member of the Special Committee on IP and Environmental Technology of the Association Internationale pour la Protection de la Propriete Intellectuelle (AIPPI). She is an active member of the Licensing Executives Society (LES), where she has served as chair of the Semiconductor Committee. She has served on the Executive Committee of the California State Bar Intellectual Property Section. She was a commercial arbitrator with the American Arbitration Association, and a Special Master and Early Neutral Evaluator for the Federal District Court for the Northern District of California. She was a member of the Inns of Court for the Northern District of California.

She is a frequent lecturer on IP strategy and IP licensing, including co-teaching a course on Global Exploitation of IP Rights at the National University of Singapore Law School, lecturing on IP Strategy in the Private Sector for the European Institute for Life Sciences in Basel, Switzerland, speaking at the Center for Intellectual Property Forum at Chalmers University in Goteborg, Sweden, and a short course on IP licensing with the University of Turin, Italy and the WIPO Academy. She regularly teaches and organizes programs on IP licensing, technology transfer, IP laws and policies relating to research institutions, and patent drafting. She has developed the WIPO curricula on Successful Technology Licensing and on Patent Drafting. I 2012 and 2011 she has taught training courses and given presentations on IP in Recife, Sao Paolo and Rio de Janeiro, Brazil. She has served as a consultant on National IP strategy for WIPO, advising the governments of the Republic of Congo and Zimbabwe in 2011 and 2012. In May, 2011 she gave a two session interactive lecture on IP at UCLA's Center for Nanosystems Innovation. In 2008, she was a guest expert at the Second Annual Asian Regional Patent Drafting Training Course sponsored by the Singapore Ministry of Foreign Affairs and WIPO. In December, 2008, she served as a guest expert and lecturer at the training workshop on Technology Licensing and Development Agreements sponsored by the Office of Intellectual Property of Brazil and the World Intellectual Property Organization, in Rio de Janeiro.

She served as a Trustee for Stanford University from 1990-1995 where she was active on the Finance and Academic Affairs Committees. She served as a member of the Stanford Medical Center Committee on Ethics. From 2008-2010 she served as a consultant on Intellectual Property for the University of California at Santa Barbara's Center for Nanotechnology and Society.

[back to top]

Tracie L. Carroll, Director, Intellectual Property & Licensing, Sanford-Burnham Medical Research Institute
Tracie L. CarrollTracie L. Carroll has served as In-House Counsel for Sanford-Burnham Medical Research Institute since 2011. As Director of Intellectual Property & Licensing she is responsible for all aspects of Sanford-Burnham’s IP management, including patent and other IP portfolio development, rights management, compliance, strategy, licensing and monetization. She works closely with the institute’s leadership, business development team, and scientists on a number of strategic collaborations and partnerships. Prior to joining Sanford-Burnham, Tracie’s practice focused on business and IP litigation, including complex business matters, commercial transactions and IP rights enforcement.

She is a licensed patent attorney who holds a J.D. with a focus certificate in Intellectual Property and CALI award in Patent Law from Whittier Law School, a M.B.A. with a concentration in Finance from Pepperdine University and a B.S. in Biology with a minor in Psychology from UCSD.

[back to top]

Jeffrey Cozzo, Account Executive, IP.com
As an Account Executive with IP.com, Jeffrey is responsible for the strategy of future produce and business development, managing strategic accounts, and enhancing customer relationships for IP.com. Jeffrey has over 15 years of consulting experience, most recently in transfer pricing where he has performed various services for multinational companies including tangible and intangible asset analyses. He was also the founding Managing Director at ktMINE and is currently the Licensing Executive Society (LES) Chicago Chapter Chair and a Certified Patent Valuation Analyst.

[back to top]

Michael Crichton, Partner, Gowling Lafleur Henderson LLP
Michael CrichtonMichael Crichton is a partner in Gowlings' Ottawa office. Michael practises primarily in the area of intellectual property litigation, with an emphasis on patent litigation covering a wide range of technologies, including mechanical, electrical, manufacturing/fabrication, communications, computer hardware and software, and related technologies. As well, he regularly acts for clients involved in disputes concerning complex trade secrets and software copyright enforcement.

Recognized in IAM Patent 1000, Managing IP's IP Patent Stars and The Best Lawyers in Canada for intellectual property law, Michael has appeared as trial counsel in a number of patent litigation proceedings. Michael is also experienced with respect to licensing of intellectual property, mediation proceedings, and Canada/U.S. cross-border intellectual property litigation and patent procurement.

Michael is a regular author on intellectual property matters, and is currently an adjunct professor of intellectual property litigation (and previously an adjunct professor of patent law) at the University of Ottawa.

[back to top]

Kirk Dailey, Head of Patent Transactions, Google
Kirk DaileyKirk Dailey has more than 20 years experience in all facets of intellectual property, including a successful track record of licensing patents, technology and trademarks. Currently, Kirk is head of patent transactions for Google and is responsible for licensing, selling and purchasing patents at Google in order to obtain freedom of action for Google.

Prior to his joining Google in 2012, Kirk was corporate vice president of intellectual property at Motorola, where he was responsible for the intellectual property business that built, maintained and leveraged a world-class IP portfolio to provide freedom of action and revenue for the business.

[back to top]

Joseph J. Daniele, PhD, Chief Operating Officer, Acorn Technologies, Inc.
Joseph J. Daniele, PhDJoe Daniele is a world expert in Intellectual Property (IP) and Technology Commercialization, with more than 30 years of experience in IP and Technology Commercialization including generating and extracting value from portfolios of patents, technology, software, etc. He has led numerous R&D and licensing efforts and completed roughly 500 IP licenses and arrangements. He has been elected to the IAM 300, The World's Leading IP Strategists annually from 2009 to present, is a Certified Licensing Professional, and serves on Boards of Advisers at companies in internet security and cancer diagnostics. Prior to Acorn, he was Senior Vice President of IP and Technology Commercialization at SAIC/Leidos, a $10+ billion Washington DC-based company. There, he established the IP Management and Technology Commercialization functions and generated significant revenue and equity commercializing the IP and technology of SAIC/Leidos and its subsidiary, Telcordia. Prior to SAIC, Joe held senior line management and corporate positions at Xerox, and founded and headed the Xerox Intellectual Capital Business Unit and the Corporate Office for Management of Intellectual Property. There, he was responsible for worldwide licensing and commercialization of all Xerox' IP including roughly 9,000 patent families and related software and technology. In his long Xerox career, he was a VC Partner in the precursor to Xerox New Enterprises, was Corporate Strategist and Science Advisor to the President, and headed Scanned Imaging Technology, and FWA Ink Jet. Prior to Xerox, he was at Philips, where he managed laser R&D through pilot manufacture for the world's first compact disc readers and burners, and early fiber optic communications. He has a BS in Electrical Engineering and a Ph.D. in Physics of Solids both from MIT, and an MBA from the University of Rochester. He has published more than 25 papers, contributed to several books, and holds 22 patents.

[back to top]

Pamela Demain, Executive Director, Business Development and Licensing, Merck & Co., Inc.
Pamela Demain is Executive Director, Business Development and Licensing, Merck & Co., Inc. She has been at Merck for over 30 years. For the past 19 years, she has negotiated transactions with companies, universities and institutions worldwide, including arrangements for compounds, research collaborations, patents, formulations, and platform technologies. Pam also heads up relationship development, which includes initiating new business development opportunities and building relationships. She was instrumental in the strategic transformation of Merck from an inward-looking to an outward-facing company. Previously, Ms. Demain spent 13 years in Worldwide Marketing in positions of increasing responsibility. Pam is currently President of the Licensing Executive Society (USA & Canada) She has been on the LES Board since 2006 and is an active member of the Life Science Sector Executive Committee since 2003. In 2012, she was honored by LES with the Frank Barnes Mentoring Award. Pam is also a Board member of BioNJ since September 2013. Pamela's pharmaceutical career began in the natural products laboratory of Gruppo Lepetit. She is a graduate of the University of Massachusetts Amherst, and received her MBA from American University in Washington, DC. She is a Certified Licensing Professional (CLP).

[back to top]

Kristine Dorrain, Director of Arbitration, Forum
Kristine Dorrain serves as Director of Arbitration for the Forum. Ms. Dorrain oversees the Forum's dispute resolution programs, including the Forum's internationally recognized domain dispute program and its traditional and arbitration and mediation programs.

At the Forum, Ms. Dorrain's work focuses on providing legal counsel and directorial oversight for the dispute resolution programs. She counsels Forum case management staff as well as ensures that Forum arbitration panelists are adhering to the Forum's Code of Procedure, where applicable, and the relevant domain name dispute rule sets. She also advises Forum on IP matters.

Additionally, Ms. Dorrain oversees the strategic development of the Forum's Arbitration and Mediation panel, including its premium IP Panel. She ensures that the FORUM's Panels include the most well-trained and experienced arbitrators and mediators in the business. Ms. Dorrain also plays a significant role in developing and marketing the Forum's overall ADR services.

Prior to joining the Forum, Ms. Dorrain was an Intellectual Property Assets Manager for Samsung Electronics. While at Samsung, she managed patent prosecution and an extensive patent case portfolio. She was responsible for preparing and evaluating invention disclosures, writing patent applications and managing research on prior art.

[back to top]

Mark Edwards, Managing Director, Bioscience Advisors Inc.
Mark EdwardsMark G. Edwards is Managing Director of Bioscience Advisors Inc., a biopharmaceutical consulting firm he founded in 2011. Previously, he was Managing Director and a Principal of Deloitte Recap LLC, a wholly-owned subsidiary of Deloitte Touche Tohmatsu. Until its sale to Deloitte in 2008, Mr. Edwards was the Managing Director and founder of Recombinant Capital, Inc. (Recap), a consulting and database firm based in Walnut Creek, California. Prior to founding Recap in 1988, Mr. Edwards was Manager of Business Development at Chiron Corporation. He is on the board of directors of the California Institute for Biomedical Research (Calibr) and AcelRx Pharmaceuticals and has previously served on the boards of Allos Therapeutics, CombiMatrix and Ontogen. Mr. Edwards received his B.A. and M.B.A. degrees from Stanford University.

[back to top]

Michael Elmer, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Michael C. Elmer has over 40 years of litigation experience at Finnegan in virtually every aspect of intellectual property law. While most of his career has been focused on litigating high-profile patent cases, he has also litigated trademark, trade secret, trade dress, copyright, and related antitrust matters. After opening the firm's Palo Alto office in 1998, Mr. Elmer created the Global IP Litigation Project in 2002, which led to the writing of "Global Patent Litigation: How and Where to Win"; and the First Global Patent Litigation Report for 2014, both published by Bloomberg BNA. The Project hosts a website containing win-rate statistics, forum shopping information and claim valuation tools for 30 countries, www.globalpatentmetrics.com. Mr. Elmer teaches Global Patent Litigation as an adjunct at the University of Washington Law School in Seattle and at the University of South Carolina Moore International School of Business. Prior to joining Finnegan he served in the U.S. Army JAG Corps where he spent two years defending patent infringement claims against the U.S. Government; and two years as Chief Trial Counsel at Ft. Ord, California, prosecuting criminal cases under the UCMJ.

J. Scott Evans, Associate General Counsel, Adobe Systems
J. Scott EvansJ. Scott received his undergraduate degree from Baylor University and his Juris Doctor cum laude in 1992 from the Louis D. Brandeis School of Law at The University of Louisville. On three separate occasions, Managing Intellectual Property magazine voted J. Scott one of the 50 Most Influential People in IP (2009, 2011, 2013). J. Scott was most recently named one of the 50 Market Shapers by World Trademark Review magazine. J. Scott is the 2015 President of the International Trademark Association, where he Chairs the Board of Directors and the Executive Committee. J. Scott served on the five-member drafting team that finalized the UDRP and the Rules of Procedure. J. Scott also served on the Implementation Review Team that crafted the Trademark Clearinghouse, URS and PDDRP. J. Scott currently works at Adobe Systems as Associate General Counsel responsible for global trademarks, copyright, domains and marketing.

[back to top]

Standish M. Fleming, Managing Member, Forward Ventures
Standish FlemingA 29-year veteran of early-stage venture capital investing, Mr. Fleming has helped raise and manage sixventure funds totaling more than $500 million and has served on the boards of 19 venture-backed companies. He has extensive experience in all aspects of venture management and finance, including fund- raising, investor relations, operations and portfolio development. He has made investments, managed portfolio companies, raised funds, pursued business development, taken companies public and successfully exited investments through public-market sales and buyouts.

In 1993, Mr. Fleming co-founded Forward Ventures. He has made investments in almost every segment of the health-care industry, including pharmaceuticals, biologics, diagnostics, devices, services and software. He has managed both platform and product companies/investments in the portfolio and led or participated in financings at all levels from pre-start-up to PIPES in public companies, in both debt and equity. He has helped start more than 15 companies and served as founding CEO of eight.

Mr. Fleming serves as a director of CONNECT, San Diego's support organization for the academic-to-early- stage community, and is a past president of the Biotechnology Venture Investors Group. Before establishing Forward Ventures, He served as the chairman, president and CEO of GeneSys Therapeutics (merged with Somatix and acquired by Cell GeneSys [NASDAQ:CEGE]). He began his venture careerSan Diego in 1986. He earned his B.A. from Amherst College and hisM.B.A. from the UCLA Graduate School of Management.

[back to top]

Brian Frizzell, Past Chair of the VTC, Director, Capstone Advisory Group
Brian FrizzellBrian Frizzell has over a decade of experience in intellectual property litigation, valuation, strategy, and licensing and has provided clients with intellectual property and financial advisory services across a wide range of industries and technologies. As part of his broad experience in supporting litigation assignments involving patents, trade secrets and other intellectual property assets, Mr. Frizzell has developed damages analyses that have been presented in federal court in a variety of jurisdictions. Additionally, Mr. Frizzell has valued large and complex patent portfolios for transactional purposes as well as part of bankruptcy proceedings. He received a B.S. in Electrical Engineering from the University of Illinois at Urbana-Champaign and a Masters in Business Administration from the Kellogg Graduate School of Management at Northwestern University. He is a past-chair for the LES Valuation and Taxation committee and currently chairs the LES Insights Editorial Board. He is also an active angel investor and member of Cornerstone Angels, a Chicago based angel investor group.

[back to top]

Mike Grey, CEO, Reneo Pharmaceuticals
Mike Grey currently serves as a venture partner at Pappas Ventures and is chairman, chief executive officer and a founder of Reneo Pharmaceuticals, Inc., a private biotechnology company. Previously he founded and was president and chief executive officer at Lumena Pharmaceuticals, Inc., a company developing treatments for pediatric and adult orphan diseases, until its acquisition by Shire plc.

Mike has 40 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies, including president and chief executive officer of Auspex Pharmaceuticals, Inc., president and chief executive officer of SGX Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2008, president and chief executive officer of Trega Biosciences, Inc., which was acquired by Lion Bioscience in 2001, and president of BioChem Therapeutic Inc. For approximately 20 years, Mike served in various roles with Glaxo, Inc. and Glaxo Holdings plc, culminating in his position as vice president, corporate development and head of international licensing.

Mike serves on the board of directors of Balance Therapeutics, Inc., BioMarin Pharmaceutical Inc., Horizon Pharma plc, Mirati Therapeutics, Inc., Selventa, Inc. and Ziarco Pharma Ltd. He received a B.Sc. in chemistry from the University of Nottingham in the United Kingdom.

[back to top]

James H. Grossman, James H. Grossman Arbitration
James H. GrossmanJames H. Grossman is an international, commercial, intellectual property, and energy focused arbitrator and mediator since 2001 with a background as an international business person and corporate securities lawyer for more than 35 years. He brings a strong business background to his role as an arbitrator and continues his business experience by serving on the boards of directors of public companies based in the United Kingdom and elsewhere which have been listed on NASDAQ, the London Stock Exchange, AIM, and the TSX (Toronto) Venture Exchange. He is a graduate of the Harvard Law School with business activities in San Francisco, London, Monaco and Geneva. In 2015 he became a director of Applaud, Inc., a new medical device company based in San Francisco with a patented IP treatment for the removal of kidney stones. Also in 2015 became director of international solar company based in the UK (part of a group with over GBP 100 million of investments in Europe) building out solar plants in the US. He is a founder and director of the Silicon Valley Arbitration and Mediation Center in Palo Alto California.

[back to top]

Lawrence (Larry) Hadley, Principal, McKool Smith
Lawrence (Larry) HadleyLawrence (Larry) Hadley is a principal in McKool Smith's Los Angeles office. Mr. Hadley has over 20 years of experience as a trial lawyer in high-stakes intellectual property and commercial litigation, including patents, copyrights, and trade secrets. Mr. Hadley's background as a commercial ship and naval officer, and as a licensed pilot, give him a unique perspective in developing persuasive case themes involving complex technology and presenting them in a clear and compelling manner to courts and juries. Mr. Hadley has litigated cases involving a wide variety of technology, including computer software and hardware, integrated circuit and processor design, wireless communications, medical devices, internet communications, compression and storage. He also has tried cases involving material sciences and plant patents.

Mr. Hadley is admitted to practice in all California state and federal courts, the U.S. Court of Appeals for the Federal Circuit, and the United States Supreme Court. He has appeared in courts across the country and has practiced before administrative bodies, including the International Trade Commission. Mr. Hadley has served as lead litigation counsel in more than a dozen trial and appellate matters and his extensive appellate experience includes more than 8 federal appellate arguments.

Mr. Hadley is a frequent commentator on legal matters involving technology. He also served as a settlement officer in the Los Angeles Superior Court Voluntary Settlement Program, and is ranked in the Best Lawyers in America as a leading lawyer in Patent Litigation.

[back to top]

Margaret Hing, Director, Business Development, La Jolla Institute for Allergy and Immunology
Margaret HingMargaret (Ng Thow) Hing joined the Institute in 2011. Ms. Hing manages the Institute’s intellectual property initiatives, including drafting and prosecuting patent applications. Ms. Hing also supports the Institute’s business development activities. Prior to joining the Institute, Ms. Hing was an attorney with Smart & Biggar, Fetherstonhaugh, a leading intellectual property and technology law firm. Ms. Hing advised clients on patent prosecution matters with a focus in the area of biotechnology.

Ms. Hing has several years of research experience and holds a Master of Science in Molecular & Medical Genetics. Her research focused on the biology and pathology of Epstein-Barr virus. Ms. Hing obtained her M.Sc. and J.D. from the University of Toronto, Canada.

[back to top]

Soonhee Jang, Vice President and Chief IP Counsel, Stratasys Ltd.
Soonhee JangMs. Soonhee Jang is Vice President and Chief IP Counsel for Stratasys Ltd., a leader in 3D printing technology where she is responsible for strategic counseling on all aspects of intellectual property and related business matters as a member of the Global Executive Management Team. Prior to Stratasys, Ms. Jang was Vice President and Chief IP Counsel for Danisco, and Vice President and Chief IP Counsel for DuPont Industrial Biosciences where she served as a member of the Senior Management Team.

Ms. Jang has extensive experience in global IP law, IP portfolio development, licensing, global IP right enforcement and patent litigation in the US, Europe and Asia working in diverse industries including biotech, pharmaceutical, health and nutrition, clean tech, chemical, and high tech.

Ms. Jang has been actively engaged in development of IP laws and policies serving as a member of the Board of Directors of the Intellectual Property Owners Association (IPO), the IPO Board Liaison of the Asian Practice Committee, and the chair of IPO’s Corporate IP Management Committee. She is also member of the amicus committee of Biotechnology Industry Organization (BIO), American Intellectual Property Law Association (AIPLA) and the Association of Corporate Patent Counsel for Chief IP Counsel (ACPC).

Ms. Jang was recognized as “One Hundred Women of Influence in Silicon Valley 2012” by the Silicon Valley/San Jose Business Journal for leadership, influence and ability to promote positive change in industry and community, and recognized as among the “Best Bay Area Corporate Counsel” in 2011 by the Silicon Valley/San Jose Business Journal and San Francisco Business Times and noted for contribution made in advancing IP laws and development in emerging market countries.

Ms. Jang is registered to practice before the USPTO and is a member of the California and New Jersey bar. Ms. Jang received her law degree from Franklin Pierce Law Center in New Hampshire, and a Master’s degree in chemistry from the University of Washington in Seattle.

[back to top]

David W. Jones, Assistant General Counsel, Microsoft
David W. JonesDavid W. Jones is the Assistant General Counsel for intellectual property policy at Microsoft . Prior to joining Microsoft in 2007, David worked as a counsel to the U.S. Senate Judiciary Committee, where he was responsible for intellectual property and antitrust matters, serving in various positions including Chief Antitrust Counsel for the Judiciary Committee and Counsel to the Intellectual Property Subcommittee. David received his legal education at the University of Virginia School of Law, and completed two appellate clerkships, one with Judge Will Garwood of the U.S. Court of Appeals for the Fifth Circuit and the other with Judge Sharon Prost of the U.S. Court of Appeals for the Federal Circuit. David began his career in the Regulatory and Appellate Litigation practice group at Sidley & Austin in Washington DC, where he worked primarily on matters involving telecommunication and internet law.

[back to top]

Justin Lewis, Chair Elect of the Valuation & Taxation Committee (VTC), Managing Director, Ocean Tomo
Justin LewisJustin Vahn Lewis is a Managing Director within the Expert Services practice area of Ocean Tomo's San Francisco office. Justin leads the firm's Intellectual Property (IP) Risk Management practice, which manages potential and future risk of intellectual property (IP) litigation.

Justin has participated and testified in many cases both as an expert witness and/or in a supporting role providing a deep bench of experience from his general litigation consulting and forensic accounting background. In addition, Justin and his team are creating innovative new products surrounding the area of intellectual property risk management.

Justin has experience in several key industries, including: automotive, biotechnology, consumer goods, manufacturing, retail, electronics (including standards based), financial services, medical devices, pharmaceutical, environmental, semiconductor, software, winemaking and computer hardware.

Specialties: Expert Testimony, Patent Damages, Intellectual Property (IP) Risk Management, Quantification of Economic Damages, Forensic Accounting

[back to top]

Jack Lu, Founding Partner and Chief Economist, IPMAP
Jack LuJack is the Founding Partner and Chief Economist of IPMAP - Intellectual Property Market Advisory Partners. His expertise includes business & assets valuation, competition study, market analysis, investment analysis, business forecast, and financial distress prediction. He has substantial experience in economic research and financial modeling for IP management and monetization, and has helped clients in developing and executing IP investment and divestiture strategies across major technology-intensive industries.

Jack is also an active researcher and publisher. His studies in intellectual property, patent markets, financial markets and other economic issues have been published by the Council on Foreign Relations, Cambridge University Press, Business Economics, Licensing Economics Review, and Les Nouvelles, the Journal of the Licensing Executives Society (LES) International. He was an expert speaker at IP forums organized by Duke Law School, LES, London IP Summit, and other entities, and his comments have appeared in CFA Magazine, Licensing Economics Review, and LES Insight. His most recent research can be found at his SSRN author page at http://ssrn.com/author=230071.

After receiving his B.E. in electrical engineering and M.Ph. in technology management, Jack studied economic policy and received his PhD from the University of Texas at Austin. He is a Chartered Financial Analyst (CFA) charter holder and a member of the CFA Institute, the National Association for Business Economics, and the Licensing Executives Society. He has been actively involved in supporting these organizations, including serving on the Executive Committees of 2011 and 2014 LES High Tech Royalty Survey.

Specialties: Business Valuation, IP Valuation, IP Financing & Investment, Start-up Company Valuation, Early-stage Technology Valuation, Business & Economic Forecast, Distressed Assets Valuation & Financial Distress Forecast, Credit Risk Analysis, Competition Study & Market Structure Analysis.

[back to top]

Douglas MacDougall, President, MacDougall Biomedical Communications
Douglas MacDougallDouglas MacDougall is the President of MacDougall Biomedical Communications with over 27 years of experience in the biotechnology industry. Doug has established an extensive industry network which he uses to assist many of his clients in fundraising, partnering and executive coaching. He has provided strategic counsel and developed innovative communications strategies for over 400 clients in the life sciences sector. Doug has been a mentor to dozens of entrepreneurs and has been an active member of the MIT Venture Mentoring Service for 10 years. Prior to founding MBI, Doug held executive management positions as CFO of Cetek Corporation, SVP of Feinstein Kean Healthcare and CFO of Applied DNA Systems. Doug has a Bachelor's degree in business administration from the Rochester Institute of Technology. He serves on the Board of Overseers of the Boston Museum of Science.

[back to top]

James A. McCarthy, CLP, Corporate & Commercial Development, Licensing and Alliance Management, CorpDev Ventures
James A. McCarthyJim has thirty years of life sciences professional experiences. His background includes a twenty-five year career with Bristol-Myers Squibb and Eli Lilly & Company and over fifteen years in international corporate business development and licensing roles. These efforts included projects and deals in over 30 countries with over 70 completed agreements across a range of transactions valued in excess of $900 million. In recent years he has been assisting small and emerging life science company to leverage their IP assets with strategic and commercial planning, venture financing, commercial initiatives and deal support on a global basis. He has commercialization and therapeutic expertise in a wide range of areas including: oncology, CNS, cardiovascular, dermatology, medical devices, ethical nutritionals. medical device pacemakers and leads, MRI technology, orphan drugs, neonatal pediatric Rx products, genetic disorders; DNA and RNAi delivery, orthopedic rehabilitation, Rx drug pricing & reimbursement, product forecasting, and venture financing etc.

He holds an MBA from Indiana University, a B.S. in Physical Therapy from SUNY Upstate Medical Center, and is a recipient of the Certified Licensing Professional (CLP) designation.

He was the founding chairperson and continues to serve as a Chairperson for the LES (USA & Canada) & LES International “Global BioPharmaceutical Royalty Rate and Deal Terms Survey”, and served on the LES Foundation Board of Directors. Jim is the 2015 Chair, of the 2,500 member, Life Sciences Sector of the Licensing Executive Society (LES) (USA & Canada).

He is active and on the BOD of Point Man Ministries, an organization to assist military combat veterans returning from foreign deployment. A passion is Climbing Colorado 14ers!

[back to top]

Matthew C. McNeill, Chief Innovation Officer, VP: IP, Technology & Strategic Alliances, Rite-Hite
Matthew has overall responsibility for Innovation and Intellectual Property, including the licensing function, which has historically concentrated on in-licensing. He is also concentrated on business development through seeking and acquiring technology for the company. This can range from strategic supply agreements, to joint development, to IP licensing, to joint ventures to IP or corporate acquisition. He has also led business development efforts in emerging technology space in which “ultra-patentes” (beyond patent) strategies had to be employed to secure sustainable competitive advantage.

Matthew has an undergraduate degree in Physics (Texas A&M) and a law degree (Boston College)

[back to top]

Mark Messenbaugh, Executive Director for Corporate Strategy & Development, SomaLogic
Mark MessenbaughMark Messenbaugh serves as SomaLogic's executive director for corporate strategy & development, where he is responsible for developing and structuring key business opportunities and third-party collaborations. Mark joined SomaLogic in 2008. Prior to that, he served as lead director for government relations for the Boys & Girls Clubs of America, where he led strategic initiatives funded by federal, state, and local governments, after starting a partnership between the organization and the office of then-Colorado Attorney General Ken Salazar. In a career spanning business strategy, law, politics, and nonprofit development, Mark has practiced corporate transactional law with the national law firms Arnold & Porter and Davis Polk & Wardwell, led business strategy war games for pharma, served as issues director for Al Gore's Presidential Campaign in 2000, helped write land-use legislation for the Colorado State Senate, and clerked for the U.S. Second Circuit Court of Appeals in New York. Mark earned a bachelor's degree in social studies from Harvard College, studied philosophy on a Fulbright Scholarship to Germany, and received his J.D. from Columbia Law School. - See more at: http://www.somalogic.com/About-Us/Our-Team/Management.aspx

[back to top]

Michael K. Milani, Managing Director, Ocean Tomo
Michael K. MilaniMichael Milani is an experienced damages expert who combines over 17 years of litigation related experience with 6 years of strategic business expertise.

As a testifying expert in Federal Court, State Court, and ADR proceedings, Mr. Milani predominantly addresses damages issues in both intellectual property (IP) matters and other types of complex commercial litigation. His range of industry experience includes consumer products, medical equipment, pharmaceuticals, semiconductors, computer networking equipment, cellular technologies, industrial products and automotive products, among others.

In addition to his work as a damages expert, Mr. Milani has experience developing comprehensive business strategies for some of America's most recognized companies and brands. He is also an adjunct professor, having taught graduate level business and law school classes on intellectual property monetization.

Mr. Milani has a bachelor of science in Finance and an MBA with concentrations in finance, marketing and strategy. He is also a Certified Licensing Professional.

[back to top]

Ada Nielsen, CEO, Foodexus LLC
Ada NielsenAda C. Nielsen, CLP, is the Chief Executive Officer of Foodexus, LLC, a company based on a new refrigeration system. Ada Nielsen is a commercialization, sales, marketing, competitive intelligence and intellectual asset strategy expert.

She is known for her proficiency in identifying commercial value in inventions and making money from inventions whether by licensing, monetizing or by developing market demand for new products.

After graduate work in theoretical physical chemistry, she became a dean of students and instructor in chemistry at Colby-Sawyer College in New London, NH. After a move to Chicago, she earned an MBA from Chicago Booth School of Business and began an industrial career in chemicals, polymers, environmental technology and energy. Her specialty is in closing deals.

She recently spent fifteen years at Amoco Chemicals & BP Upstream monetizing non-strategic technology in Chemicals and then creating and implementing an invention management/commercialization system for Exploration & Production.

Her affiliations and honors include:

Distinguished Fellow of

  • Licensing Executives Society International (for Chemicals, Energy, Environment & Materials) Inaugural group


  • Commercial Development & Marketing Association Award
  • Named as one of the Top 300 International Intellectual Asset Strategists in 2013 and 2014 (IAM Magazine)

Advisory Boards

  • Illinois Institute of Natural Resource Sustainability Advisory Board
  • Illinois Natural Resources and Conservation Board (Statutory position, appointment by the Governor)

Non-Profit Leadership Roles

  • Chair, LES Wisconsin Chapter, 2014
  • Co-Chair, IP100, an invitation-only event held 1st Q each year for senior licensing executives (founded in 2010 by Ada Nielsen when president of LES)

Former roles:

  • President, Licensing Executives Society (USA and Canada), 2010
  • Education Chair, LES Wisconsin, 2013
  • Chair, Education, LES International
  • Chair, Chemicals, Energy, Environment & Materials, LES International
  • Intellectual Property Owners, Chair, Valuation and Taxation Committee
  • Lake Forest (IL) Ad Hoc Environmental Board
  • Secretary, Division of Small Chemical Businesses, American Chemical Society
  • President, Commercial Development & Marketing Association


  • American Society of Mechanical Engineers
  • Association of University Technology Managers
  • Product Development & Marketing Association
  • Society of Petroleum Engineers

She earned an A.B. in Chemistry from Wellesley College, Wellesley, MA, and studied theoretical physical chemistry at Tulane University (NSF Fellowship) in New Orleans and at Dartmouth College, Hanover, NH. She also earned an MBA from Chicago Booth School of Business with a concentration in finance and marketing, and is a Certified Licensing Professional.

[back to top]

Stacey Nunes, Strategic Partnerships, National Research Council of Canada
Stacey NunesMr. Stacey Nunes is in charge of Strategic Partnerships for the Life Sciences division of the National Research Council of Canada (NRC). He has over 20 years experience in research and development and has been involved in the commercialization and transfer of technology from government laboratories for the past 12 years. He helps manage a portfolio of over 100 patent families, and is responsible for developing collaborations with industry and licensing NRC technology. He has led two start-up initiatives at NRC to commercialize engineering-based green technologies. He was the first Canadian ever invited to present his technology at the National Association of Seed and Venture Funds’ (NASVF) World’s Best Technologies Showcase. He has made international presentations on the commercialization of technology in Mexico City (2011 and 2012) and at BIO 2012. His publications include one on commercialization of R&D from government labs, presented at the 2008 RnD Management Conference. He holds a BSc in Chemistry from York University and an MBA from the University of Ottawa, and also studied International Business at Reims University in France.

[back to top]

Niall O'Donnell, Ph.D, Managing Director, RiverVest
Niall O'DonnellNiall O'Donnell joined RiverVest® in 2006 as a Kauffman Fellow and became a managing director in 2014. He focuses on biopharmaceutical, diagnostic and medical device opportunities and contributes to the formation, development and business strategies of RiverVest portfolio companies.

Dr. O'Donnell is a board member of Lyric Pharmaceuticals and co-founder of Reneo Pharmaceuticals. Dr. O'Donnell was a board observer and acted as interim chief medical officer at Lumena Pharmaceuticals, Inc. where he was central to the development and execution of its clinical strategy prior to the company's acquisition by Shire plc in 2014. He also served on the board of Excaliard Pharmaceuticals, Inc., which was acquired by Pfizer Inc. Dr. O'Donnell helped co-found and seed Excaliard, develop the company's clinical strategy and is a co-inventor on several key Excaliard patents. He was an observer at Mpex Pharmaceuticals, Inc., which was acquired by Aptalis Pharma, and at Otonomy, Inc., which completed its initial public offering in 2014.

Prior to joining RiverVest, Niall spent five years as an immunologist at Johnson & Johnson Pharmaceutical Research and Development in San Diego. He was part of a successful cross-disciplinary team of chemists and biologists that drove small molecule anti-inflammatory drugs into clinical trials. Niall co-authored the first paper validating the newly discovered histamine H4receptor as a key regulator of immune pathologies.

Niall earned his Ph.D. in Biochemistry from the University of Dundee, Scotland, and M.A. in Biochemistry from Pembroke College, Oxford. He also received an M.B.A. from the Rady School of Management of the University of California, San Diego. His professional affiliations include the American Thoracic Society, American Association of Immunologists and the Society of Glycobiology.

[back to top]

Brian P. O'Shaughnessy, Shareholder, RatnerPrestia
Brian O'ShaughnessyBrian P. O'Shaughnessy is a shareholder in the intellectual property law firm of RatnerPrestia, Washington, DC. He is a registered patent attorney with over 25 years' experience in all aspects of intellectual property law. He works with innovators in establishing global IP portfolios, and in structuring IP-related transactions. He represents clients in federal courts, the International Trade Commission, and in diverse proceedings before the US Patent and Trademark Office.

In addition to his day job, Brian is Regional Vice President, USA, of the Licensing Executives Society (USA & Canada), Inc., and has served on the LES Board of Trustees since 2007. As Regional Vice President, he is responsible for articulating the Society's position on legislation, administrative policy, and trends in IP law in the U.S. He is an author, editor, and longstanding faculty member of the LES Professional Development Series.

Brian earned a law degree from the Syracuse University College of Law, Syracuse, N.Y. Prior to that, he earned BS and MS degrees from the Department of Chemistry, Rochester Institute of Technology, Rochester, N.Y. He now serves on the RIT Board of Trustees as a member of its Executive Committee and Chair of its Student Life Committee.

[back to top]

Sandra Partridge, Managing Director, Forum
Sandra Partridge heads the Business Development efforts for the company, employing her marketing and management expertise along with her law degree.

She is licensed to practice law in Pennsylvania and holds a Juris Doctorate from the Dickinson School of Law of the Pennsylvania State University where she focused her legal studies on arbitration and mediation. Sandra is also a graduate of the Cornell ILRB Mediation program.
Sandra spent more than 20 years as a retail executive and consultant holding senior operations and marketing positions at several national retailers. Sandra was vice president of the New York office of the American Arbitration Association before joining the company.

[back to top]

Afshin Pishevar, Chief Legal Officer and General Counsel, Hyperloop Technologies, Inc.
Afshin PishevarAfshin Pishevar (“AP”) has been representing corporations and individuals in a diverse array of nationally noteworthy, high-profile matters. With legal and business experience spanning over two decades, AP has significant experience in transportation law, having represented numerous industry companies, inter alia, a recognized ride-sharing service in the District of Columbia. His practice involved Corporate, Business, Transportation, Technology, IP, Criminal & Civil Litigation, Trial Practice, as well as Immigration Law, Commercial Landlord/Tenant, and Torts. An active member of Bar and other professional associations, AP has served in leadership roles such as Committee Chair and President for over 20 years. He has served as General Counsel to the non-profit organization, Define American, helping with various corporate, pro bono and other legal matters. He has also been active in regulatory and public policy affairs. He has served as trustee and advisor to various political leaders and executives in the area of local and national transportation infrastructure and High Speed Rail. AP is a team-builder whose depth and breadth of experience in legal and business matters enable him to solve complex issues and challenges with finesse, creativity, and efficiency. Prior to starting his law firm, he was an associate at a large law firm, summer law clerk to a Federal Judge and law clerk for the State Attorney's Office and the Legal Aid Society. Throughout his career, he has been dedicated to public service, having received awards and recognitions for his efforts. AP is a Captain in the Reserves, JAG Unit–Maryland Military Defense Force (MDDF). Most recently, he was honored in the Top 25 list of Washingtonian Magazine’s year-end legal review (ranked #8 for DC, MD and VA). AP is steadfastly devoted to ensuring the realization of Hyperloop and the tremendous benefit it will convey to the world’s future. AP received his BA from University of Maryland (College Park) and his Juris Doctorate from Cleveland State University's Cleveland-Marshall College of Law where he was keynote speaker at the Commencement Ceremony

[back to top]

David Poon, Senior Director for External R&D and Alliances, Zymeworks
David is the Senior Director for External R&D and Alliances at Zymeworks. He currently oversees and manages Zymeworks' strategic collaborations with Celgene Corp., Eli Lilly & Co., and Merck & Co. and other in- and out-licensing activities. During his tenure at Zymeworks, David also held various positions including overseeing all wet-lab operations and made key contributions to the development of the Azymetric™ and AlbuCORE™ platforms. David received his Ph.D. in Chemistry from the University of British Columbia with a focus on studying the structure-function relationship of enzymes using NMR spectroscopy.

[back to top]

Linda Pullan
Linda PullanAfter a Ph.D. in Biochemistry, Linda Pullan has over 25 years of industry experience, starting in drug discovery at Monsanto/Searle/now Pfizer and ICI/Zeneca/now AstraZeneca. She led teams that put Seroquel, a multi-billion dollar antipsychotic, and other molecules into development. Business development began with in-licensing technology and early drug candidates at AstraZeneca, and continued as head of oncology & hematology licensing for Amgen. She then joined Kosan Biosciences as VP of Business Development, focusing on out-licensing. She also served as CEO of Viriome and on the board of Paloma and of IRAD.

For several years, she has been providing help in identification, evaluation, valuation, negotiation and strategy for partnering, in or out. She has an extensive deal sheet ranging from company acquisitions to Phase III compounds to preclinical candidates to technologies.

She writes a free monthly newsletter Pullan's Pieces (see www.PullanConsulting.com ), on science & business for thousands of readers.

[back to top]

Eric Reifschneider, Senior Vice President and General Manager, Qualcomm Technology Licensing
Eric ReifschneiderEric Reifschneider serves as senior vice president and general manager of Qualcomm Technology Licensing (QTL) where he is responsible for managing the day-to-day operations and providing oversight and strategic direction to QTL's Business Development, Legal, Finance, Market Analysis, Contract Compliance, and Audit organizations. He also plays a leading role in negotiating Qualcomm's significant licensing deals and driving continued growth in QTL's existing and future licensing programs.

Before joining Qualcomm, Reifschneider was a partner in the Palo Alto, California office of an international law firm, where he chaired the global technology and intellectual property group. Earlier in his career, Reifschneider was the head of the technology transactions group of a major Silicon Valley-based law firm.

Reifschneider holds a Juris Doctor from Harvard Law School, where he graduated magna cum laude and served as Executive Editor of the Harvard Law Review, and bachelor of science degrees in physics and mathematics from M.I.T., where he graduated first in his class and was named the top male scholar-athlete in his senior class. He has served on the board of directors of the M.I.T. Club of Northern California and was the director of the Club's semiconductor entrepreneurship program.

[back to top]

Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer, Spectrum Pharmaceuticals
Rajesh C. Shrotriya, MDIn September 2000, Dr. Shrotriya joined the Company as President and Chief Operating Officer and in August 2002, he was appointed Chief Executive Officer. In this capacity he has spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc.

Previously, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research.

Dr. Shrotriya is a 2011 Ernst & Young Orange County Region Entrepreneur of the Year® award winner. Dr. Shrotriya was specifically cited for his turn-around of Spectrum. The Ernst & Young LLP award program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Dr. Shrotriya was chosen from 15 finalists by a panel of independent judges.

[back to top]

Prathiba M. Singh, Senior Advocate, Delhi High Court
Prathiba M. SinghMrs Singh is a leading Intellectual Property lawyer in India. She has the distinction as being the only IP lawyer designated as a Senior Advocate by the Delhi High Court in December 2013.

Mrs. Singh is an alumnus of Cambridge University U.K. She has instituted the Prathiba M Singh Scholarship for LLM students was instituted at Cambridge University, which grants complete scholarships to Indian student/s pursuing their LLM.

Mrs Singh has the unique distinction of having handled landmark matters in all fields of IP law. She has successfully defended Indian pharmaceutical companies in the well acclaimed Novartis matter before the Hon'ble Supreme Court of India. She has also handled multiple litigations for telecom giants for enforcing various Standard Essential Patents in the field of Telecommunications. She has also dealt with a large number of trade mark cases, advertising related cases including disparagement, comparative advertising etc and copyright litigation as well.

In contentious matters Mrs. Singh is consulted and briefed by a large number of leading law firms/corporates with respect to IPR litigation in India. She has been appointed as Amicus Curiae to streamline the working of the Copyright Office.

Prior to her designation, she was the Managing Partner of Singh & Singh Law Firm LLP, which is among India's leading IP Litigation firms. She successfully represents both Indian as well as international clients in IP matters, and also deals with Telecom and Broadcasting matters. She appears on a regular basis in the Hon'ble Supreme Court, High Court of Delhi, Intellectual Property Appellate Boards, Trademark and Patent Office, and has about 200 reported cases to her credit.

[back to top]

Jonathan D. Spangler, Vice President and Chief Patent Counsel, NuVasive, Inc.
Jonathan D. SpanglerJonathan D. Spangler joined NuVasive in 2001 and has served as Vice President and Chief Patent Counsel since December 2004. Over that time, NuVasive has grown from a niche player in the US spine market (revenue of $2.1MM in 2001) to a global leader in spinal innovation with offices worldwide (~$762MM revenue currently) and a full complement of spinal products. Prior to joining NuVasive, Mr. Spangler served as Chief Patent Counsel for A-Med Systems, Inc., a medical technology company. Prior to that, he practiced law at Arnold White & Durkee specializing in patent and trade secret litigation involving medical devices and at Haugen & Nikolai specializing in patent prosecution involving medical devices. He also worked at the United States Patent and Trademark Office, where he examined patent applications and graduated from the Patent Training Academy. Mr. Spangler received a B.S. in Biomedical Engineering (with a minor in Electrical Engineering) from Marquette University, and a J.D. from the University of Dayton School of Law. He is licensed to practice in California, in Minnesota, and before the United States Patent and Trademark Office.

[back to top]

D. C. Toedt III, Attorney, Law Office of D.C. Toedt III
D. C. Toedt IIID. C. Toedt III is an attorney and arbitrator who has negotiated scores of license agreements in his career. He teaches advanced contract drafting at the University of Houston Law Center and currently serves as program co-chair for LES's Houston chapter. He was formerly vice-president and general counsel of BindView Corporation, a 500-employee, publicly-traded software company (which as outside counsel he had helped the founders to start) until the company's successful "exit" when it was acquired by Symantec.& Before that he was a partner and member of the management committee of Arnold, White & Durkee, a 150-lawyer IP litigation boutique law firm. Admitted to practice in Texas and California, he is a former co-chair of the State Bar of California Business Law Section's Commercial Transactions Committee and previously served on the governing council of the ABA Section of Intellectual Property Law.

[back to top]

Scott Weingust, Intellectual Property Valuation Practice, Stout Risius Ross, Inc. (SRR)
Scott WeingustScott Weingust leads the Intellectual Property Valuation Practice at Stout Risius Ross, Inc. (SRR) . He has over 18 years of experience providing consulting services to corporations, law firms, investment firms, universities, and other organizations primarily in the areas of intellectual property ("IP") valuation, disputes, and licensing. Mr. Weingust has provided testimony as a damages and valuation expert in IP-related litigation including claims associated with patent infringement, trade secret misappropriation, breach of contract, constructive fraud, tortious interferences, and unfair competition. He has valued and/or priced IP and other intangible assets for a variety of purposes including licensing negotiations, purchase/sale, litigation, internal strategic decision-making, use of IP for raising capital, transfer pricing and other tax-related issues, financial reporting, and regulatory compliance, among others. Mr. Weingust is currently an adjunct faculty member at The John Marshall Law School in Chicago where he teaches a course on IP valuation.

[back to top]

Jeffrey S. Whittle, Partner and Head of Technology Law Section, Bracewell & Giuliani, LLP
Jeffrey S. WhittleJeffrey Whittle is currently responsible for Education on the Board of Trustees of LES (USA & Canada), an instructor for the Education Committee, and an International Delegate to and Co-Chair of the Education Committee for LES International. Jeff also served as Sponsorship Trustee for LES (USA & Canada) (2011- 2012), Houston Chapter Board Member (2009-1010), and Houston Chapter President (2007-2008). He is a Certified Licensing Professional (CLP) and a frequent speaker and author, nationally and internationally, on various licensing/technology topics.

Jeff is an Intellectual Property and Technology attorney with the international law firm of Bracewell & Giuliani LLP, where he is a partner, shareholder, and the International Head of the Technology Law Section. He is listed in Chambers USA America's Leading Lawyers for Business, Intellectual Property; Legal 500 Patent Prosecution: Litigation and Design Patents/ Technology: Transactions; IAM Licensing 250: The World's Leading Patent & Technology Licensing Lawyers; and IAM Patent 1000: The World's Leading Patent Practitioners.

Jeff also is a graduate of Vanderbilt University (BEEE) and Wake Forest University (MBA, JD), is on the Law Board of Visitors for Wake Forest University School of Law, and is licensed to practice law in Texas, New York, Florida, and North Carolina, before the U.S. Patent and Trademark Office, and before numerous federal district and appellate courts, including the Federal Circuit Court of Appeals and U.S. Supreme Court.

[back to top]

David Winwood, Chief Business Development Officer, Pennington Biomedical Research Center
David WinwoodDavid Winwood is Chief Business Development Officer at Pennington Biomedical Research Center, the first person appointed to this position.

A graduate of the University of East Anglia (B.Sc., M.Sc., Ph.D.) and North Carolina State University (M.A.), Winwood has experience in academia and the private sector, including basic research, drug delivery, business development, company formation, licensing and management of university intellectual property and economic development activities at the University of Alabama at Birmingham (UAB), North Carolina State University and The Ohio State University.

He has held research, business development and company leadership roles in three startup businesses, with responsibilities including fund raising and corporate partnership and in adjunct professor appointments at The Ohio State University, North Carolina State University and UAB.

Winwood is designated a Registered Technology Transfer Professional by The Alliance of Technology Transfer Professionals, an international body for professionals engaged in technology transfer.

Dr. Winwood is President-Elect of the Association of University Technology Managers®, AUTM®.

He is a member of the Executive Committee of Southeast Bio, the Technology Transfer committee of BIO and the Executive Committee of the Council on Governmental Relations. He previously served as an appointed member of the Council on Competitiveness' Regional Innovation Initiative Expert Committee.

[back to top]

Dr. Koenraad Wuyts, Chief Intellectual Property Officer, KPN Group
Koenraad WuytsKoenraad Wuyts (51) graduated in Physics in 1992 and became Bachelor in Philosophy in the same year, both at the University of Leuven. He entered the intellectual property arena in 1994 and qualified as European Patent Attorney in 1999.

Nowadays Koenraad Wuyts is Chief Intellectual Property Officer of the KPN Group companies. The group develops ICT operations worldwide. Before working with KPN, Koenraad Wuyts was the head of patents and licensing at the research center IMEC (Belgium). Over the last ten years of his career Koenraad Wuyts developed extensive experience in patent portfolio management and the broad range of IPR law, currently lecturing frequently at international conferences.

He still lives in Belgium and is the happy father of three young adults.

[back to top]


11130 Sunrise Valley Drive, Suite 350 Reston, VA 20191 Phone: 703-234-4058 Fax: 703-435-4390